You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 301 No. 14, April 8, 2009 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related article
 •Related letters
 •Similar articles in JAMA
 Topic Collections
 •Bacterial Infections
 •Pulmonary Diseases
 •Chronic Obstructive Pulmonary Disease
 •Pneumonia
 •Statistics and Research Methods
 •Drug Therapy
 •Adverse Effects
 •Drug Therapy, Other
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The systematic review and meta-analysis by Dr Drummond and colleagues1 drew on 11 randomized controlled trials involving inhaled corticosteroids of 6 months or longer duration in COPD to suggest that inhaled corticosteroid therapy was not associated with a survival benefit in these patients. However, a pooled analysis by Sin et al2 drew on 6 of the 11 trials (references 10, 11, 14, 34, 36, and 37 in Drummond et al). It came to the conclusion that inhaled corticosteroids were associated with a 27% reduction in all-cause mortality in stable COPD, although none of the 6 studies (whose follow-up ranged from 9 to 42 months) were designed to evaluate mortality as an end point in either review.

The difference in conclusions could be because Drummond et al analyzed more trials (11 vs 6) or because the duration of follow-up was different (1 vs 2-3 years). We believe that . . . [Full Text of this Article]

James Wall, MRCP
jamewall@hotmail.com

Imran Aziz, FRCP
Department of Respiratory Medicine
Royal Albert Edward Hospital
Wigan, Lancashire, England



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Inhaled Corticosteroids in Patients With Stable Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis
M. Bradley Drummond, Elliott C. Dasenbrook, Marshall W. Pitz, David J. Murphy, and Eddy Fan
JAMA. 2008;300(20):2407-2416.
ABSTRACT | FULL TEXT  

RELATED LETTERS

Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease
Yoon K. Loke and Sonal Singh
JAMA. 2009;301(14):1432.
EXTRACT | FULL TEXT  

Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease
Finn Radner and Ulf Nihlén
JAMA. 2009;301(14):1433.
EXTRACT | FULL TEXT  

Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease—Reply
M. Bradley Drummond and Eddy Fan
JAMA. 2009;301(14):1433-1434.
EXTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.